Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma

Treatment options for patients with heavily pretreated relapsed and/or refractory multiple myeloma remain limited. We evaluated a novel therapeutic regimen consisting of carfilzomib, pomalidomide, and dexamethasone (CPD) in an open-label, multicenter, phase 1, dose-escalation study. Patients who rel...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Blood
Asıl Yazarlar: Shah, Jatin J., Stadtmauer, Edward A., Abonour, Rafat, Cohen, Adam D., Bensinger, William I., Gasparetto, Cristina, Kaufman, Jonathan L., Lentzsch, Suzanne, Vogl, Dan T., Gomes, Christina L., Pascucci, Natalia, Smith, David D., Orlowski, Robert Z., Durie, Brian G. M.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: American Society of Hematology 2015
Konular:
Clinical Trials and Observations
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4643003/
https://ncbi.nlm.nih.gov/pubmed/26384354
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2015-05-643320
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller